Immunotech Biopharm Ltd
6978.HKHKSEHealthcareBiotechnology
Latest quote
HK$0.39
+HK$0.005 · +1.30%
6978.HK company overview
Regular session · HKT · Market data may be delayed.
Company profile
Company websiteImmunotech Biopharm Ltd operates as a biopharmaceutical firm specializing in cellular immunotherapy. Its primary activities involve the investigation, development, and market introduction of T cell-based immunotherapy solutions for various cancers within the People's Republic of China. The company's flagship product, EAL, is a multi-target cellular immunotherapy currently undergoing Phase II clinical trials for the purpose of preventing liver cancer recurrence after surgery. Furthermore, Immunotech Biopharm is conducting both preclinical and clinical research on EAL for its potential use in treating lung cancer, glioma, gastric cancer, and colorectal cancer. Other pipeline assets include the 6B11-OCIK injection, which is in Phase I trials for ovarian cancer; the CAR-T-19 injection product, targeting B-cell acute lymphoblastic leukaemia; and a range of TCR-T cell products designed for solid tumor treatment. Established in 2006, the company's main office is located in Beijing, China.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- CN
- CEO
- Jian Zhang
- Listed since
- Jul 10, 2020
- Employees
- 183
Market position
52-week range
Current HK$0.39
- Open
- HK$0.39
- Previous close
- HK$0.385
- Volume
- 292K
- 0.39× average
- Average volume
- 746.09K
- Average daily volume
- Market cap
- 240.83M HKD
- Beta
- 0.12
- Market reference 1
- 50-day average
- HK$0.4769
- -18.22% below average
- 200-day average
- HK$1.943
- -79.93% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 1.83B CNY
- EV / EBITDA
- -10.84×
- Earnings yield
- -15.97%
- Free cash flow yield
- -7.75%
Profitability & efficiency
- Return on equity
- 1656.40%
- Return on assets
- -38.26%
- Return on invested capital
- -32.83%
Financial health
- Current ratio
- 0.35×
Financial statements
Income trends
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 53.87M CNY | — | — | — | — |
| Gross profit | −53.87M CNY | — | — | — | — |
| Research and development | 85.39M CNY | 154.24M CNY | 177.33M CNY | 69.76M CNY | 93.6M CNY |
| Selling, general, and administrative | 41.04M CNY | 44.54M CNY | 53.22M CNY | 97.71M CNY | 104.25M CNY |
| Operating expenses | 115.49M CNY | 198.78M CNY | 230.55M CNY | 273.93M CNY | 344.86M CNY |
| Interest income | 518.23K CNY | 1.07M CNY | 5.51M CNY | 3.2M CNY | 7.56M CNY |
| Interest expense | 6.63M CNY | 6.42M CNY | — | 6.14M CNY | 3.68M CNY |
| Depreciation and amortization | 55.3M CNY | 52.22M CNY | 52.22M CNY | 43.11M CNY | 21.01M CNY |
| Operating income | −155.8M CNY | −198.78M CNY | −230.55M CNY | −273.93M CNY | −344.86M CNY |
| Net income | −230.79M CNY | −186.91M CNY | −334.82M CNY | −318.11M CNY | −354.22M CNY |
Company facts updated Aug 24, 2026.
Earnings
- Latest fiscal-year EPS
- -0.42
- FY2025
- Latest fiscal-year revenue
- 0 CNY
- FY2025
Annual EPS trend
Reported history and fiscal-year consensus
Annual revenue trend
Reported history and fiscal-year consensus
6978.HK peers
Continue in GoAI
Research 6978.HKresearch.disclaimer